When compared to treatment with a NFκB inhibitor alone, we found PEDF treatment alone demonstrated superior ability to reduce BC cell viability and downregulate pro-metastatic biomarkers under post-menopausal conditions in ER+/HER2- BC, and under pre-menopausal conditions in TNBC cells. The gene discussed is NFKB1; the disease is breast cancer.